Elanco Animal Health Incorporated $ELAN Shares Sold by Sector Gamma AS

Sector Gamma AS reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 38.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 292,073 shares of the company's stock after selling 185,000 shares during the period. Elanco Animal Health comprises approximately 1.4% of Sector Gamma AS's holdings, making the stock its 28th biggest position. Sector Gamma AS owned 0.06% of Elanco Animal Health worth $4,171,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in ELAN. Nuveen LLC acquired a new position in Elanco Animal Health during the 1st quarter worth $115,212,000. Dimensional Fund Advisors LP grew its holdings in Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after acquiring an additional 2,563,740 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. ASR Vermogensbeheer N.V. bought a new position in shares of Elanco Animal Health in the 1st quarter worth about $23,744,000. Finally, DDD Partners LLC lifted its position in shares of Elanco Animal Health by 202.7% in the 1st quarter. DDD Partners LLC now owns 1,492,992 shares of the company's stock worth $15,676,000 after buying an additional 999,716 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ELAN shares. Piper Sandler raised their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective on the stock in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $20.00.

Elanco Animal Health Stock Up 0.6%

ELAN stock opened at $21.77 on Friday. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $21.82. The company has a market capitalization of $10.82 billion, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 3.97 and a beta of 1.65. The firm's 50-day moving average is $19.23 and its two-hundred day moving average is $15.08. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm earned $0.30 EPS. Elanco Animal Health's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.